<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633839</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-301-007</org_study_id>
    <nct_id>NCT02633839</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults</brief_title>
  <official_title>A Phase 1 Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety
      of a single dose of CVT-301 in smoking and non-smoking adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>within 30 min prior to CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma drug concentration (tmax)</measure>
    <time_frame>within 30 min prior to CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>within 30 min prior to CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function</measure>
    <time_frame>within 90 min prior to CVT-301 dose and at specified time points up to 24 hours post-dose</time_frame>
    <description>Pulmonary function will be measured by spirometry using the guideline specified by the Third National Health and Nutrition Examination Survey (NHANES III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events (AEs) including Serious AEs</measure>
    <time_frame>up to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Adults who smoke</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults who don't smoke</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301</intervention_name>
    <description>Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.</description>
    <arm_group_label>Adults who smoke</arm_group_label>
    <arm_group_label>Adults who don't smoke</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>Administered orally according to the carbidopa dosing schedule.</description>
    <arm_group_label>Adults who smoke</arm_group_label>
    <arm_group_label>Adults who don't smoke</arm_group_label>
    <other_name>Lodosyn ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 18 to 32 kg/m2;

          -  Forced expiratory volume in one second (FEV1) ≥80% of predicted for race, age, sex,
             and height;

          -  FEV1/FVC (forced vital capacity) ratio ≥70%;

          -  Smokers are defined as those currently smoking at least 10 cigarettes/day for at least
             12 months with a positive urinary cotinine result and with no past (within 5 years) or
             present history of intrinsic lung disease (e.g. asthma, chronic obstructive pulmonary
             disease [COPD], chronic bronchitis, or other relevant conditions);

          -  Non-smokers are defined as those who never smoked or were exposed to less than 1 pack
             year within at least 12 months and with a negative urinary cotinine result.

        Exclusion Criteria:

          -  Subject who is not surgically sterile or female subject who is less than 2 years
             postmenopausal, and who does not agree to use a highly effective birth control method
             during the study and up to 3 months after the last dose of investigational product;

          -  Any flu-like syndrome or other respiratory infections within 2 weeks prior to the
             Screening Visit;

          -  History of chronic obstructive pulmonary disorder (COPD) requiring intermittent or
             continuous use of any oral or inhaled medication therapy within last 3 years;

          -  Renal impairment as defined by a calculated creatinine clearance of ≤ 80 mL/minute;

          -  History of syncope within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Murck, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 001</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 002</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

